These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 32338853)

  • 21. Cervical cord area is associated with infratentorial grey and white matter volume predominantly in relapsing-remitting multiple sclerosis: A study using semi-automated cord volumetry and voxel-based morphometry.
    Bellenberg B; Schneider R; Weiler F; Suchan B; Haghikia A; Hoffjan S; Gold R; Köster O; Lukas C
    Mult Scler Relat Disord; 2015 May; 4(3):264-72. PubMed ID: 26008944
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Altered Cerebrospinal Fluid Neurofilament Light Chain but Not Neurogranin Levels Are Associated with Response to Ocrelizumab Treatment in Relapsing-Remitting Multiple Sclerosis: A Preliminary Study.
    Kızılay T; Akbayir E; Erol R; Demir AS; Özkan Yaşargün D; Yilmaz V; Tuzun E; Turkoglu R
    Eur Neurol; 2024; 87(4):203-210. PubMed ID: 38754397
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis.
    Barro C; Benkert P; Disanto G; Tsagkas C; Amann M; Naegelin Y; Leppert D; Gobbi C; Granziera C; Yaldizli Ö; Michalak Z; Wuerfel J; Kappos L; Parmar K; Kuhle J
    Brain; 2018 Aug; 141(8):2382-2391. PubMed ID: 29860296
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bimonthly assessment of magnetization transfer magnetic resonance imaging parameters in multiple sclerosis: a 14-month, multicentre, follow-up study.
    Mesaros S; Rocca M; Sormani M; Valsasina P; Markowitz C; De Stefano N; Montalban X; Barkhof F; Ranjeva J; Sailer M; Kappos L; Comi G; Filippi M
    Mult Scler; 2010 Mar; 16(3):325-31. PubMed ID: 20086023
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum neurofilament is associated with progression of brain atrophy and disability in early MS.
    Kuhle J; Nourbakhsh B; Grant D; Morant S; Barro C; Yaldizli Ö; Pelletier D; Giovannoni G; Waubant E; Gnanapavan S
    Neurology; 2017 Feb; 88(9):826-831. PubMed ID: 28148632
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A semiautomated measure of whole-brain atrophy in multiple sclerosis.
    Bermel RA; Sharma J; Tjoa CW; Puli SR; Bakshi R
    J Neurol Sci; 2003 Apr; 208(1-2):57-65. PubMed ID: 12639726
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasma neurofilament light chain in children with relapsing MS receiving teriflunomide or placebo: A post hoc analysis of the randomized TERIKIDS trial.
    Kuhle J; Chitnis T; Banwell B; Tardieu M; Arnold DL; Rawlings AM; Geertsen SS; Lublin AL; Saubadu S; Truffinet P; Kappos L
    Mult Scler; 2023 Mar; 29(3):385-394. PubMed ID: 36632983
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fatigue and brain atrophy in Egyptian patients with relapsing remitting multiple sclerosis.
    Khedr EM; Desoky T; Gamea A; Ezzeldin MY; Zaki AF
    Mult Scler Relat Disord; 2022 Jul; 63():103841. PubMed ID: 35526475
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cortical and Subcortical Morphometric and Iron Changes in Relapsing-Remitting Multiple Sclerosis and Their Association with White Matter T2 Lesion Load : A 3-Tesla Magnetic Resonance Imaging Study.
    Al-Radaideh A; Athamneh I; Alabadi H; Hbahbih M
    Clin Neuroradiol; 2019 Mar; 29(1):51-64. PubMed ID: 29299614
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chronic cerebrospinal venous insufficiency and iron deposition on susceptibility-weighted imaging in patients with multiple sclerosis: a pilot case-control study.
    Zivadinov R; Schirda C; Dwyer MG; Haacke ME; Weinstock-Guttman B; Menegatti E; Heininen-Brown M; Magnano C; Malagoni AM; Wack DS; Hojnacki D; Kennedy C; Carl E; Bergsland N; Hussein S; Poloni G; Bartolomei I; Salvi F; Zamboni P
    Int Angiol; 2010 Apr; 29(2):158-75. PubMed ID: 20351672
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Secondary-progressive form of multiple sclerosis: MRI changes versus clinical status.
    Masek M; Vaneckova M; Krasensky J; Danes J; Havrdova E; Hrebikova T; Seidl Z
    Neuro Endocrinol Lett; 2008 Aug; 29(4):461-6. PubMed ID: 18766142
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Brain atrophy and physical disability in primary progressive multiple sclerosis: A volumetric study.
    Galego O; Gouveia A; Batista S; Moura C; Machado E
    Neuroradiol J; 2015 Jun; 28(3):354-8. PubMed ID: 26246109
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis.
    Bridel C; Leurs CE; van Lierop ZYGJ; van Kempen ZLE; Dekker I; Twaalfhoven HAM; Moraal B; Barkhof F; Uitdehaag BMJ; Killestein J; Teunissen CE
    Neurology; 2021 Nov; 97(19):e1898-e1905. PubMed ID: 34504023
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Baseline serum neurofilament light chain levels differentiate aggressive from benign forms of relapsing-remitting multiple sclerosis: a 20-year follow-up cohort.
    Arroyo Pereiro P; Muñoz-Vendrell A; León Moreno I; Bau L; Matas E; Romero-Pinel L; Martínez Yélamos A; Martínez Yélamos S; Andrés-Benito P
    J Neurol; 2024 Apr; 271(4):1599-1609. PubMed ID: 38085343
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical utility of the Lumipulse™ immunoassay for plasma neurofilament light chain in multiple sclerosis.
    Nicolella V; Fiorenza M; Monteiro I; Novarella F; Sirica R; D'Angelo M; Carbone G; La Civita E; Esposito A; Criscuolo V; Carotenuto A; Petracca M; Lanzillo R; Castaldo G; Morra VB; Terracciano D; Moccia M
    J Neurol Sci; 2024 Aug; 463():123115. PubMed ID: 38964268
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Whole-brain N-acetylaspartate concentration: correlation with T2-weighted lesion volume and expanded disability status scale score in cases of relapsing-remitting multiple sclerosis.
    Bonneville F; Moriarty DM; Li BS; Babb JS; Grossman RI; Gonen O
    AJNR Am J Neuroradiol; 2002 Mar; 23(3):371-5. PubMed ID: 11901002
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Blood neurofilament light chain as a biomarker of MS disease activity and treatment response.
    Kuhle J; Kropshofer H; Haering DA; Kundu U; Meinert R; Barro C; Dahlke F; Tomic D; Leppert D; Kappos L
    Neurology; 2019 Mar; 92(10):e1007-e1015. PubMed ID: 30737333
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Brain atrophy in relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis: longitudinal quantitative analysis.
    Ge Y; Grossman RI; Udupa JK; Wei L; Mannon LJ; Polansky M; Kolson DL
    Radiology; 2000 Mar; 214(3):665-70. PubMed ID: 10715027
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasma neurofilament light levels are associated with risk of disability in multiple sclerosis.
    Manouchehrinia A; Stridh P; Khademi M; Leppert D; Barro C; Michalak Z; Benkert P; Lycke J; Alfredsson L; Kappos L; Piehl F; Olsson T; Kuhle J; Kockum I
    Neurology; 2020 Jun; 94(23):e2457-e2467. PubMed ID: 32434867
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cerebrospinal fluid levels of neurofilament and tau correlate with brain atrophy in natalizumab-treated multiple sclerosis.
    Mellergård J; Tisell A; Blystad I; Grönqvist A; Blennow K; Olsson B; Dahle C; Vrethem M; Lundberg P; Ernerudh J
    Eur J Neurol; 2017 Jan; 24(1):112-121. PubMed ID: 27699930
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.